Sci Rep:肺癌患者生活质量的社会人口学、临床和遗传决定因素

2018-07-14 xiangting MedSci原创

多种因素影响肺癌患者的QOL,基线QOL可以影响生存率。

患者汇报的健康相关生活质量(QOL)是癌症患者整体健康状况的主要组成部分,与预后有关。

这项研究在6,420名肺癌患者中,确定了QOL的患者特征和遗传决定因素。使用来自SF-12调查问卷的患者反应计算标准化躯体部分总分(PCS)和精神部分总分(MCS)。此外,研究人员分析了p38 MAPK信号通路中的218个单核苷酸多态性(SNPs),p38 MAPK信号通路是细胞和环境应激反应的关键介质,被作为研究群体亚组中QOL的遗传决定因素(N = 641)。

平均PCS和MCS的人口学因素趋势包括吸烟状况(PCS P趋势<0.001,MCS P趋势<0.001)和教育程度(PCS P趋势<0.001,MCS P趋势<0.001)。MCS也有类似的关联。MEF2B的纯合稀有基因型:rs2040562使得较差MCS的风险升高(OR:3.06,95%CI:1.05-8.92,P=0.041)。最后,生存分析显示,低PCS或MCS与5年死亡率风险升高(分别为HR = 1.63,95%CI:1.51-1.77,HR = 1.23,95%CI:1.16-1.32)和中位生存时间显著减少相关(Plog-rank<0.001)。

这些结果表明,多种因素影响肺癌患者的QOL,基线QOL可以影响生存率。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1671022, encodeId=b05216e1022a4, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Fri Mar 15 14:03:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990644, encodeId=b77c199064476, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed May 29 12:03:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616877, encodeId=04aa16168e7a2, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Mon Jul 16 02:03:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331519, encodeId=f4483315199b, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Jul 14 11:20:17 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1671022, encodeId=b05216e1022a4, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Fri Mar 15 14:03:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990644, encodeId=b77c199064476, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed May 29 12:03:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616877, encodeId=04aa16168e7a2, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Mon Jul 16 02:03:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331519, encodeId=f4483315199b, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Jul 14 11:20:17 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1671022, encodeId=b05216e1022a4, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Fri Mar 15 14:03:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990644, encodeId=b77c199064476, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed May 29 12:03:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616877, encodeId=04aa16168e7a2, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Mon Jul 16 02:03:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331519, encodeId=f4483315199b, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Jul 14 11:20:17 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1671022, encodeId=b05216e1022a4, content=<a href='/topic/show?id=bd58310846e' target=_blank style='color:#2F92EE;'>#决定因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=31084, encryptionId=bd58310846e, topicName=决定因素)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e7726816052, createdName=wushaoling, createdTime=Fri Mar 15 14:03:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1990644, encodeId=b77c199064476, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82222, encryptionId=5739822223f, topicName=肺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f612331, createdName=gds2009, createdTime=Wed May 29 12:03:00 CST 2019, time=2019-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1616877, encodeId=04aa16168e7a2, content=<a href='/topic/show?id=e660e3936c0' target=_blank style='color:#2F92EE;'>#社会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73936, encryptionId=e660e3936c0, topicName=社会)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e6de19781024, createdName=ms705947299214030, createdTime=Mon Jul 16 02:03:00 CST 2018, time=2018-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=331519, encodeId=f4483315199b, content=阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/fhZdOu27e88Voqh19n8eF8cLplo8L4nicKtH0WnE3KFELXns5XDu8rsiceK2HHDZc2SEStia5VV3Pia2QLMVqlWbHw/0, createdBy=6e012139475, createdName=神功盖世, createdTime=Sat Jul 14 11:20:17 CST 2018, time=2018-07-14, status=1, ipAttribution=)]
    2018-07-14 神功盖世

    0

相关资讯

Sci Rep:miR-143和miR-506联合多重活动抑制肺癌细胞周期和体外血管生成

结合RNA测序数据的通路分析,这项研究结果确定了联合miR转染作为肺癌治疗的可行策略,值得进一步研究。

Sci Rep:肺癌病理图像综合分析发现预测生存结局的肿瘤形态和边界特征

这项研究为肿瘤形态与患者预后之间的关联提供了新的见解。

Ann Oncol:绝经后女性口服双磷酸盐或能预防肺癌

2018年6月,发表在《Ann Oncol》的一项由美国学者进行的研究,考察了绝经后女性口服双磷酸盐与肺癌发病率之间的相关性。

Ann Oncol:纳尼 维生素D的循环浓度影响肺癌风险?

2018年6月,法国、英国、澳大利亚等国学者在《Ann Oncol》发表了一项在肺癌队列联盟(LC3)中进行的20项前瞻性研究的分析,考察了维生素D的循环浓度与肺癌风险之间的相关性

CLIN CANCER RES:EGFR突变肺癌中与EGFR酶抑制剂耐药有关的基因突变

CLIN CANCER RES近期发表了一篇文章,研究与EGFR酶抑制剂治疗效果有关的分子因素,寻找耐药机制。作者使用靶向二代测序技术分析了EGFR突变肿瘤治疗前与接受EGFR TKI治疗后进展的肿瘤分子情况。

中央型肺癌1例

男,80岁,查体发现右上方占位2周